DiscoveryBioMed, Inc. (DBM) is a biotechnology company located in Birmingham, AL formed with the ultimate goal of integrating human cell physiology with the drug discovery critical path. DBM’s founder, Erik Schwiebert, Ph.D., a physiologist by trade, launched the company in 2007. Since then, DBM has continued to grow and gain recognition both locally and nationally. DiscoveryBioMed’s mission is to fill a critical niche within the drug discovery industry by specializing in custom human cell engineering and drug discovery. Our R&D infrastructure and know-how are leveraged as a CRO service to support the drug discovery community by integrating human cell platforms within the drug discovery critical path. DBM uses the most physiologically relevant human cell platforms with the purpose of improving attrition rate and yielding high value clinical candidates. DBM refers to our novel scientific approach and niche within this marketplace as Humanized Drug Discovery.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Adiponectin Inducer Lead ADN12 and Back-up Lead ADN18 Chemical Classes
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):